Advertisement
Markets

Bausch & Lomb: Cast a Cautious Eye

This lens-care company's stock has taken a beating -- and some analysts don't expect it to heal anytime soon.

To a blurry eye, Bausch Lomb's beaten-up share price might look like a buying opportunity. If your vision is clear, it's not.

The stock (symbol BOL) has plummeted 20% since Monday, when the company said it would temporarily stop shipments of its ReNu with MoistureLoc contact lens solution. The reason: fear that the product might be connected with a rare fungal eye infection. The stock market could be overreacting. It did, after all, do just that to Sherwin-Williams in February after a jury found the company liable in a lead-paint case. That stock lost one-fifth of its value in a single day. But it has recovered almost fully as the market reassessed the implications to Sherwin-Williams' businesses and found them less than dire.

Advertisement - Article continues below

However, with Bausch Lomb, savvy investors would be wise to hold off rather than expect a quick bounceback, analysts say. Although there's no evidence that the infections are caused by the firm's product, the uncertainty is great and the full implications unknown.

The Centers for Disease Control and Prevention is investigating several reports of Fusarium keratitis infections. The cause of the infections has yet to be determined, "although evidence thus far remains concerning" for BL, says Suey Wong, an analyst at Robert W. Baird Co. Nearly all of the infected patients so far reviewed by the CDC have said they used ReNu products. How long the investigation will take isn't clear. But in the meantime, the brand name is tainted. Major retail chains are pulling ReNu products from their shelves.

Advertisement
Advertisement - Article continues below

This is a big deal for BL. It generates 23% of its sales from lens-care products, sold under the Bausch Lomb, Boston, ReNu and Sensitive Eyes names. It launched ReNu with MoistureLoc in 2004. Bank of America analyst David Maris says that brand isn't likely to return to the U.S. market, resulting in the loss of $45 million in potential sales this year. He figures BL will lose share of the overall lens care market and that its contact lens sales could be hurt as well. "We think the brand damage on ReNu will be sizable and carry over into the Bausch Lomb overall brand globally," he says. On Wednesday, Maris lowered his 2006 earnings per share estimate from $4.24 to $3.05. He also lowered his 12-month target price for the stock from $49 to $40 and maintains a "sell" rating.

Maris also wonders what the company will say to some questions about its handling of the situation, including why doctors weren't notified sooner and the timeline wasn't explained better to investors. Such worries could add to the long-term problems for the firm, in his view.

BL has more worries than ReNu. Competition among eye-care companies -- including Johnson Johnson, Alcon and others -- is tough. Analysts acknowledge that BL hasn't invested enough in research and development, resulting in a weak product pipeline. Wong, who rates the stock "neutral," points out that a recent accounting scandal at a subsidiary in Brazil caused the company to restate five years of financial results and that accounting at a Korean subsidiary is also under investigation. BL said this week that it would further delay its 10-K filing.

--Lisa Dixon

Advertisement

Most Popular

12 Tax Deadlines for July 15 (It's Not Just the Due Date for Your Tax Return)
tax deadline

12 Tax Deadlines for July 15 (It's Not Just the Due Date for Your Tax Return)

Between due dates for IRA or HSA contributions, paying estimated taxes and other deadlines, there's more to do by July 15 than just filing your federa…
July 10, 2020
Know Why Your Credit Score Changes: 9 Money Moves to Consider
credit & debt

Know Why Your Credit Score Changes: 9 Money Moves to Consider

Your credit score is a key indicator of your financial well-being and of the risk you pose to lenders. How good is yours?
July 10, 2020
65 Best Dividend Stocks You Can Count On
stocks

65 Best Dividend Stocks You Can Count On

These 65 Dividend Aristocrats are an elite group of dividend stocks that have reliably increased their annual payouts every year for at least a quarte…
July 8, 2020

Recommended

Closing Bell 7/13/20: This Is Your Market on (Coronavirus) Drugs
Markets

Closing Bell 7/13/20: This Is Your Market on (Coronavirus) Drugs

A rapid rally to start the week, sparked by encouraging vaccine news from Pfizer and BioNTech, collapsed in the afternoon.
July 13, 2020
Closing Bell 7/10/20: Gilead Gives Stocks a Booster Shot
Markets

Closing Bell 7/10/20: Gilead Gives Stocks a Booster Shot

Stocks rallied out of negative territory Friday after Gilead announced that remdesivir helped reduce COVID-19 mortality risk in a clinical trial.
July 10, 2020
2020 Stock Market Holidays and Bond Market Holidays
Markets

2020 Stock Market Holidays and Bond Market Holidays

Is the market open today? Take a look at which holidays the stock markets and bond markets take off in 2020.
July 10, 2020
Closing Bell 7/9/20: Another Split Market as Jobs Concerns Grow
Markets

Closing Bell 7/9/20: Another Split Market as Jobs Concerns Grow

A mounting list of planned playoffs weighs on stocks Thursday, though Big Tech manages to hoist the Nasdaq up to another record high.
July 9, 2020